0
Skip to Content
Arvalus Therapeutics
Arvalus Therapeutics
Arvalus receives 2.2€ Million funding from DZIF
Christian Brandstetter 4/4/25 Christian Brandstetter 4/4/25

Arvalus receives 2.2€ Million funding from DZIF

Arvalus secures €2.2 million DZIF FlexFund!

Read More
Lisa Osbelt-Block on television as part of the 3sat Talkshow “Scobel - Biotop Mensch”
Christian Brandstetter 4/2/25 Christian Brandstetter 4/2/25

Lisa Osbelt-Block on television as part of the 3sat Talkshow “Scobel - Biotop Mensch”

Our Co-founder Lisa Osbelt-Block was a guest on the latest edition of Gert Scobel's science talk show Wissen hoch 2 on ZDF/3sat.

Read More
AMR Conference: Winning the poster price and gaining valuable insights
Arvalus Team 2/28/25 Arvalus Team 2/28/25

AMR Conference: Winning the poster price and gaining valuable insights

AMR Conference: Winning the poster price and gaining valuable insights..

Read More
Helmholtz Enterprise Kick-off in Berlin
Christian Brandstetter 1/28/25 Christian Brandstetter 1/28/25

Helmholtz Enterprise Kick-off in Berlin

Kick-off for the Helmholtz Enterprise grant with all teams in Berlin.

Read More
Arvalus receives Helmholtz Enterprise grant
Christian Brandstetter 1/24/25 Christian Brandstetter 1/24/25

Arvalus receives Helmholtz Enterprise grant

Arvalus receives Helmholtz Enterprise grant for 14 months.

Read More
INCATE has selected Arvalus as a promising startup to tackle antimicrobial resistance
Christian Brandstetter 12/21/24 Christian Brandstetter 12/21/24

INCATE has selected Arvalus as a promising startup to tackle antimicrobial resistance

INCATE has selected Arvalus as a promising startup for tackling antimicrobial resistance.

Read More
Live Biotherapeutic Products
Christian Brandstetter 12/2/24 Christian Brandstetter 12/2/24

Live Biotherapeutic Products

What are Live Biotherapeutic Products (LBT)?

Read More


Imprint


Data protection